EMA chooses first two drugs for adaptive licensing scheme
This article was originally published in SRA
Executive Summary
The European Medicines Agency has selected the first two medicines to enter its pilot adaptive licensing project, out of a total of 20 applications received from companies so far. It is considering four more as potential candidates to be included at a later stage, has rejected three as being unsuitable, and is still evaluating the remaining 11.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.